MEDICAL LETTER ON DRUGS AND THERAPEUTICS
metrics 2024
Informed Decisions for Optimal Drug Therapy
Introduction
MEDICAL LETTER ON DRUGS AND THERAPEUTICS is a pivotal resource for professionals in the fields of medicine and pharmacology, published by MED LETTER INC. Since its inception in 1965, this journal has been committed to elucidating the complexities of drug therapy and clinical therapeutics, offering readers evidence-based insights and critical evaluations of the latest medications and treatment protocols. With a quarterly ranking reflecting its stature—Q4 in Medicine (Miscellaneous) and Q3 in both Pharmacology and Pharmacology (Medical)—the journal maintains a specific niche ensuring readers are equipped with updated information that continues to influence healthcare practices. Although it does not operate under an open access model, the journal is accessible to institutions and professionals eager to stay at the forefront of medicinal advancements. The importance of this journal lies in its dedication to enhancing pharmacological knowledge, thus catering to the needs of researchers, healthcare providers, and students alike, making it an essential addition to the literature in therapeutic drug interventions.
Metrics 2024
Metrics History
Rank 2024
Scopus
IF (Web Of Science)
JCI (Web Of Science)
Quartile History
Similar Journals
Australian Prescriber
Advancing Evidence-Based Prescribing.Australian Prescriber is a distinguished open-access journal published by Therapeutic Guidelines Ltd, aiming to advance the field of pharmacology and medical prescriptions. Since its inception in 1994, this journal has been dedicated to disseminating essential findings and insights related to therapeutic guidelines and pharmaceutical care, making it an invaluable resource for healthcare professionals and researchers alike. With an ISSN of 0312-8008 and an E-ISSN of 1839-3942, it caters to an audience that values evidence-based medicine, empowering practitioners with knowledge to enhance clinical practice. The journal currently holds a Q2 ranking in the Pharmacology (medical) category and is recognized in the 51st percentile among its peers, reflecting its significant contributions to the medical field. Available from 1995 to 2024, this journal not only serves as an academic platform but also a critical discussion forum for professionals keen on improving pharmacological practices in Australia and beyond.
Journal of Pharmaceutical Health Care and Sciences
Bridging disciplines to elevate pharmaceutical practices.The Journal of Pharmaceutical Health Care and Sciences is a premier open access journal published by BMC that aims to advance the field of pharmaceutical sciences by providing high-quality research and comprehensive reviews across various domains including pharmacology, nursing, and healthcare. With an impact factor reflecting its relevance and rigor, the journal has established itself as a significant platform for disseminating knowledge since its inception in 2015. The journal is indexed in Scopus, currently holding a position in the Q3 quartile for medical pharmacology and Q2 quartile for nursing pharmacology, indicating its growing influence and reach in the scientific community. Based in the United Kingdom with a commitment to open access, the Journal of Pharmaceutical Health Care and Sciences ensures that all researchers, professionals, and students have free access to vital research that fosters innovation and improves healthcare outcomes worldwide. With a focus on collaborative and multidisciplinary approaches, the journal invites contributions that align with its objectives of enhancing health care delivery and pharmaceutical practices.
DRUGS
Unveiling Breakthroughs in Drug DevelopmentDRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.
Biuletyn Wydzialu Farmaceutycznego Warszawskiego Uniwersytetu Medycznego
Bridging Gaps in Pharmaceutical Science and PracticeBiuletyn Wydzialu Farmaceutycznego Warszawskiego Uniwersytetu Medycznego is a prestigious academic journal dedicated to publishing high-quality research in the field of pharmaceutical sciences. Published by the Medical University of Warsaw, this journal serves as a vital platform for researchers, professionals, and students to share their findings and advances in drug development, pharmaceutical sciences, and clinical practices. With its ISSN 2080-1602, it upholds rigorous standards of academic integrity and relevance to the pharmaceutical community. Although it currently does not offer open access, the journal plays a crucial role in disseminating knowledge, contributing to the advancement of pharmacy and health sciences. Located in Warsaw, Poland, it aims to bridge gaps in pharmaceutical research and practice, fostering collaboration and innovation among professionals in the field.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
Fostering collaboration in the realm of cardiovascular pharmacology.JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.
CURRENT PHARMACEUTICAL DESIGN
Pioneering Insights in Pharmacology and Drug DevelopmentCURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.
CLINICAL THERAPEUTICS
Empowering clinicians with evidence-based therapeutic advancements.Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.
FUNDAMENTAL & CLINICAL PHARMACOLOGY
Fostering excellence in pharmacological sciences and clinical practice.FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.
Annales Pharmaceutiques Francaises
Navigating the Frontiers of Pharmaceutical InnovationAnnales Pharmaceutiques Francaises, an esteemed journal published by MASSON EDITEUR, serves as a pivotal platform in the field of Pharmaceutical Science and Pharmacology. Established in 1945 and continuing through 2024, this journal showcases significant contributions to the advancement of pharmaceutical sciences, bridging the gap between research, development, and practical applications. Although it currently does not offer open access, its established reputation and Q3 ranking in both Pharmaceutical Science and Pharmacology highlight its role in disseminating impactful studies. With an ISSN of 0003-4509, the journal is indexed in Scopus, boasting a respectable percentile ranking for both domains, and remains a vital resource for researchers, professionals, and students dedicated to exploring the latest advancements in the pharmaceutical field. Based in France, at 21 Street Camille Desmoulins, Issy, 92789 Moulinais Cedex 9, it aims to foster a deeper understanding of pharmacological innovations and therapeutic agents among its diverse readership.
Journal of Taibah University Medical Sciences
Exploring the Frontiers of Medical Science TogetherWelcome to the Journal of Taibah University Medical Sciences, a distinguished open-access publication dedicated to advancing knowledge in the field of medicine. Since its inception in 2006, and published by ELSEVIER, this journal has become a vital resource for researchers and healthcare professionals alike, reflecting a steadfast commitment to disseminating innovative research and high-quality medical studies. With an impressive impact factor and a Scopus ranking placing it in the top 25% of general medicine journals, this publication occupies a notable position in the academic landscape. The journal covers a wide array of topics within the medical sciences, from clinical research to public health initiatives. As a Q3 category journal in the 2023 rankings, it continues to attract submissions that contribute meaningfully to the diverse and evolving field of medicine, supporting an open-access model that ensures widespread accessibility to its invaluable content. Explore the Journal of Taibah University Medical Sciences to stay abreast of the latest scientific advancements and engage with fellow scholars across the globe.